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Abstract 
Background: Sepsis and septic shock is characterized by oxidative stress that mainly promotes systemic inflamma-
tion and organ failure due to excessive free radical production and depletion of antioxidant defenses. Therefore, we 
investigated the effect of selenium administration on antioxidant status, levels of cytokines and clinical outcomes.
Methodology: This study was a prospective randomized control trial (RCT) whereby patients received selenium as 
sodium selenite (2 mg IV bolus followed by 1.5 mg continuous infusion for 14 days) plus standard therapy. The control 
group received standard therapy without selenium. The primary endpoint was 28-day mortality. The changes in the 
mean levels of glutathione peroxidase (GPX) activity, IL-6, IL-8 and IL-10, the incidence of ventilator-associated pneu-
monia (VAP) and other secondary endpoints were also recorded. VAP was broken down into early VAP and late VAP to 
see the clinical significance of each. We also recorded any adverse outcomes from selenium infusion.
Results: Over 24-month period, 54 patients were recruited and randomized and an intention to treat (ITT) princi-
ple was applied (selenium, n = 29; control, n = 25) in the final analysis. There was no statistically significant differ-
ence between the two groups in 28-day mortality although it was lower in the selenium group compared with the 
control group: 9 (31 %) in the selenium versus 10 (40 %) in the control groups (p = 0.49). At day 0, GPX activity was 
0.185 ± 0.3 versus 0.19 ± 0.3 U/mL (p = 0.9), day 3, GPX activity was 0.52 ± 0.5 versus 0.17 ± 0.2 U/mL (p = 0.02), 
at day 7 it was 0.55 ± 0.5 versus 0.24 ± 0.3 U/mL (p = 0.032), at day 10 it was 0.62 ± 0.7 versus 0.33 ± 0.4 U/mL 
(p = 0.048) and at day 14 it was 1.1 ± 1 versus 0.89 ± 1 U/mL (p = 0.70) for the selenium versus control groups, 
respectively. However, there were no significant differences between the mean plasma levels of all the three inflam-
matory cytokines at any point in time between the two groups. There was a significant reduction in occurrence of VAP 
in the selenium group compared with the control group (55.2 versus 84 %, p = 0.023), respectively.
Conclusion: High-dose selenium administration within the time frame of early goal-directed therapy was not 
resulted in reduction of 28-day mortality, but increased the activity of glutathione peroxidase with no effect on the 
levels of inflammatory cytokines at any point in time in mechanically ventilated septic patients. However, selenium 
supplementation in mechanically ventilated patients following sepsis was associated with reduced occurrence of VAP.
Trial registration: IRCT201212082887N4 at WHO Clinical Trial Registry, August 29, 2014
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Background
Sepsis constitutes a major health care problem. The inci-
dence of severe sepsis has increased over time and the 
projected estimate is increased by 1.5 % ever year due to 
number of reasons [1–3]. Population data suggested that 
severe sepsis is the leading cause of hospitalization and 
accounted for 2  % of all hospital admission, with 59  % 
of the patients requiring admission to the intensive care 
unit (ICU) [4]. Although the mortality of severe sepsis 
and septic shock decreased over time, it is still remaining 
unacceptably high [3, 5].
A number of studies suggested that inflammatory 
cytokines and oxidative stress released during sepsis were 
higher in septic patients and their concentrations were 
associated with severity and evolution of organ dysfunc-
tions and death [6–9]. In the initial phase of the disease, 
there is an overwhelming inflammation, whereby migra-
tion of the neutrophils into the inflamed tissue releases 
free radicals that damage the endothelium and epithe-
lium tissue leading to capillary congestion, leukocyte and 
macrophage infiltration into the site of inflammation of 
the respiratory system leading to respiratory failure [10]. 
Consequently, they acquire nosocomial respiratory tract 
infections after 48 h of mechanical ventilation; ventilator-
associated pneumonia (VAP) [11]. It has been reported 
that ventilator-associated pneumonia is affecting more 
than 30  % of those susceptible patients and increasing 
morbidity, mortality, length of ICU stay and costs [12–
15]. Hence, therapies counteracting the inflammation 
and oxidative stress and the consequences are attractive. 
One of those therapies seems to be selenium supplemen-
tation. Selenium is an essential trace element for the bio-
synthesis and function of about 25 known selenocysteine 
containing selenoproteins, located on the catalytic center 
of most selenoenzymes [16]. One of the best known and 
characterized redox systems is glutathione complex con-
sisting of the selenium-dependent peroxidases and the 
thioredoxin reductases [17, 18]. Study suggested that 
selenium plays an important role as anti-inflammatory 
agent by tightly regulating the expression of proinflam-
matory genes in immune cells [19, 20].
Low plasma selenium levels are associated with an 
increasing risk of nosocomial infections [21]. Daily infu-
sion of 1600  µg selenium following initial bolus dose of 
2000 µg for 10 days was also found to be a novel therapy 
that increases Se status, improves illness severity, and 
lowers the incidence of hospital-acquired pneumonia 
for systemic inflammatory response syndrome (SIRS) 
patients in ICU [10]. However, randomized trials and 
their pooled data involving parenteral selenium supple-
mentation in critically ill patients with sepsis have yielded 
contradictory results [22–26]. Currently, we do not have 
concrete evidences that support the administration of 
selenium in septic patients. Therefore, doing trials that 
incorporated biomarkers to optimize treatment effects 
could build the bodies of literatures and help clinicians 
that need evidence-based medicine. We hypothesized 
selenium administration within the time frame of early 
goal-directed therapy in mechanically ventilated patients 
following sepsis (1) reduces 28-day mortality by 20 % (2) 
reduces oxidative stress and inflammation (3) reduces 
ventilator-associated pneumonia.
Methods
Study design and patient selection
This was a prospective, randomized, single blind, sin-
gle center clinical trial conducted on 54 septic patients 
admitted to ICU of Sina Hospital of Tehran Univer-
sity of Medical Sciences (TUMS). Consecutive patients 
were recruited from 2012 to December 2014. The study 
was conducted in accordance with the declaration of 
Helsinki and approved by the ethics committee of Teh-
ran University of Medical sciences international campus 
(TUMS-IC) [code of ethical approval: 1-1: 90-3-29]. Oral 
and written informed consent was obtained from the 
patients or their close relatives. Moreover, an identifica-
tion code was used instead of patient´s name to protect 
the patient´s identity when reporting trial-related data.
Inclusion and exclusion criteria
We included patients of age ≥17 years with sepsis, severe 
sepsis and septic shock, enrolled into the study after 
diagnosis within 6  h, if the patient was on mechani-
cal ventilation  >48  h and if they had informed consent 
either from the patient or the relative. On the other hand, 
patients were excluded if they were of age  <17  years, if 
they were pregnant, if they had missing informed consent 
either from the patient or the relative, if they participated 
before in this clinical trial, if they had cancer as the cause 
of SIRS or sepsis, chronic kidney diseases and if medical 
staff decided to limit care.
Randomization and protocol
Consecutive eligible patients were recruited and rand-
omized via block randomization into four blocks, in which 
a random selection was done using a list of numbers gen-
erated using statistical software. Half of the patients in 
each block were allocated to selenium and the remaining 
half to control group. Boxes containing the whole treat-
ment for each patient were delivered to the investigator by 
the hospital pharmacist following the order of the rand-
omization list. All patients remained blinded throughout 
the study period. Standard treatments for severe sepsis 
and septic shock were given according to the surviving 
sepsis campaign (SSC) [27] guidelines. Patients in sele-
nium group were received 2000 µg of sodium selenite in 
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100 mL of normal saline within the first 6 h of diagnosis 
of sepsis during 1 h intravenously followed by 1500 µg of 
sodium selenite in 250 mL of normal saline during 12 h 
continuously for 14  days. The control groups received 
standard therapy without selenium. Patients otherwise 
were treated according to the best practice of the hospi-
tal, including parenteral or enteral nutrition together with 
vitamins and trace elements as necessary. The interven-
tion drug was supplied by Biosyn Arzneimittel GmBH 
(Fellbach, Germany).
Definitions
Sepsis, severe sepsis and septic shock were defined 
according to criteria proposed by the American College 
of Chest Physicians/Society of Critical Care Medicine 
[28]. Standard treatments for severe sepsis and septic 
shock were implemented as following: measurement of 
lactate levels, appropriate diagnosis studies to ascertain 
causative organisms before starting antibiotics, early 
administration of broad spectrum antibiotic therapy, 
early fluid administration to target Central Venous Pres-
sure (CVP) of 8–12  mmHg and central venous oxygen 
saturation (SvO2) >70 %, hypotension control with vaso-
pressor [27]. Additional works accomplished within 24 h 
as appropriate were low dose steroid, glycemic control 
(blood glucose  <150  mg/dL), lung protective ventila-
tion and standard prophylactic measures for deep vein 
thrombosis (DVT) and stress related mucosal damage 
(SRMD). We defined VAP as pneumonia that occurs 
48–72  h or thereafter following endotracheal intuba-
tion, characterized by the presence of a new or progres-
sive infiltrate, signs of systemic infection (fever, altered 
white blood cell count), changes in sputum characteris-
tics, and quantitative detection of a causative agent; early 
VAP <5 days, late VAP ≥5 days of mechanical ventilation 
[29]. SOFA respiratory score was calculated based on 
PaO2/FiO2 (mmHg)—SOFA score <400, 1; <300, 2; <200 




We recorded the following data: demographic data, vital 
signs, severity scores by calculating APACHE II score, 
SOFA score, comorbidities, and type of infection based 
on culture results.
Laboratory data
We recorded data on hematological, biochemical data 
analysis, blood gas (for determination of (PaO2/FiO2), 
blood cultures and cultures of specimen drawn from 
the site of infection on randomization and then as 
appropriate.
Follow‑up
Patients were followed up for 90  day or till they died, 
depending which happened first. The following variables 
were collected on days 3, 7, 10 and 14 after randomiza-
tion: vital signs, SOFA respiratory scores and stand-
ard laboratory tests. Cultures of specimens drawn from 
any new site of infection were performed throughout 
the ICU stay. Duration of mechanical ventilation, dura-
tion of vasopressor support, duration of ICU and hos-
pital stays, the incidences of new infection, incidence of 
ARDS, 28-day mortality and overall mortality were also 
recorded. The occurrence of VAP was noted throughout 
the ICU stay along with any adverse reaction as a result 
of selenium infusion.
Outcome measures
The primary outcome was 28-day mortality. Changes in 
GPX activity, IL-6, IL-8 and IL-10 in different points in 
time of study, duration of mechanical ventilation, dura-
tion of ICU and hospital stays and incidence VAP. We 
also evaluated VAP as early VAP versus late VAP and the 
effect of each on some clinical outcomes and health care 
resource consumption measures.
Sample collection, handling and analysis
Blood samples (5  mL each) were taken from central 
venous catheters and arterial lines. The first sample was 
obtained upon diagnosis of sepsis, but prior to initiation 
of the therapy. Other samples were obtained on days 3, 
7, 10, and 14 after randomization. The blood samples 
were collected into vacutainer tubes containing EDTA 
and spun these samples at 3000×g for 10–15  min to 
remove cells and cellular debris. The cell-free superna-
tant and plasma were stored at −80 °C until the time of 
the analyses. The levels of GPX, IL-6, IL-8 and IL-10 were 
analyzed via automated platinum ELISA kit (Human Cu/
ZnOD, Affymetrix eBioscience, Vienna, Austria) in Mas-
soud laboratory, an independent laboratory found in 
Northern part of Tehran, Iran following the manufactur-
ing’s instruction. All other routine laboratory activities 
were carried out in the hospital laboratory according to 
the prescription of the attending clinicians.
The primary end point was 28-day mortality in the 
selenium groups and control group. A sample size calcu-
lation was carried out using these parameters: alpha-level 
0.05, statistical power level 0.8, anticipated effect size of 
0.2. This resulted to a suggested sample size of 90 patients 
based on the results of previous study [30]. However, the 
recruitment process was so slow that we included only 
54 patients in our final analysis according to ITT princi-
ple. Recruitment process was so slow due to the fact that 
Sina hospital is trauma center I which gives services for 
patients referred from other centers in the country. Since 
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we are caring for much debilitated patients referred from 
other centers that require intensive monitoring and our 
restricted inclusion criteria, we could not get as many 
patients as we planned.
Statistical analysis
Discrete variables are expressed as counts (percent-
age) and continuous variables as mean  ±  standard 
deviation (SD). Categorical data were compared 
using Fisher’s exact test or Pearson Chi-square test. 
A Kolmogorov–Smirnov test was used to verify the 
normality of distributions of continuous variables. 
Continuous variables conforming to a normal distri-
bution were compared using Student’s t test otherwise 
the Mann–Whitney U test was applied. Changes in 
SOFA respiratory scores and plasma cytokines levels 
over time as a function of group were analyzed by per-
forming the two-way repeated-measures of variance 




We assessed 364 patients for eligibility, of which 310 
patients were excluded for the following reasons: 257 
patients were excluded for not fulfilling the inclusion 
criteria, 2 patients decline not to participate and 51 
patients for different reasons as described in detail in 
Fig.  1. Finally, 54 patients fulfilling the inclusion crite-
ria recruited over a 2-year period (Selenium =  29, con-
trol =  25) were included in our final analysis according 
to the ITT principle although selenium was discounted 
in 3 patients due to rise in serum creatinine by the order 
of the senior clinician after 2 days of infusion. All patients 
followed either till they died or for 90  days, whichever 
happened first.
Patient characteristics at randomization
There were no significant differences between the two 
patient groups for the general characteristics at randomi-
zation. The median (IQR) age of patients included was 35 
(177–82) years for selenium group and it was 41 (19–82) 
years for the control group, of which 46 patients (85.2 %) 
were male. The mean SOFA, APACHE II score and PaO2/
FiO2 on the day of admission were similar in both groups. 
The severity, the site of infection and the type of organ-
ism involved did not significantly differ between the two 
groups at baseline as shown in Table 1.
Study endpoints
28-day mortality There was no statistically significant 
difference between the two groups in 28-day mortality 
although it was lower in the selenium group compared 
with the control group; 9 (31  %) in the selenium group 
compared with 10 (40 %) in the control group, (p = 0.49).
Change in GPX, IL-6, IL-8 and IL-10 At day 0, GPX 
activity was 0.185 ± 0.3 versus 0.19 ± 0.3 U/mL (p = 0.9); 
day 3, GPX activity was 0.52 ± 0.5 versus 0.17 ± 0.2 U/
mL (p = 0.02); at day 7, it was 0.55 ± 0.5 versus 0.24 ± 0.3 
U/mL (p  =  0.032); at day 10, it was 0.62  ±  0.7 versus 
0.33 ± 0.4 U/mL (p = 0.048) and at day 14 it was 1.1 ± 1 
versus 0.89 ± 1 U/mL (p = 0.70) for the selenium versus 
control groups, respectively. The GPX levels reached sig-
nificant levels at day 3 and continued to rise till day 14. 
There were no significant differences between the mean 
plasma levels of all the three inflammatory cytokines at 
any point in time between the two groups as shown in 
Table 2 and Figs. 2, 3, 4.
Clinical outcomes The mean SOFA respiratory scores 
on the day of randomization (2.3 ± 0.8 versus 2.4 ± 0.8, 
p = 0.82) and day 3 (2.5 ± 0.9 versus 2.4 ± 0.9, p = 0.69) 
were similar in the selenium and control groups, respec-
tively. However, the mean SOFA respiratory scores 
decreased significantly only in the selenite versus control 
group, respectively (2.1 ± 1 versus 2.7 ± 1, p = 0.03) at 
day 7 and (1.6 ± 1.2 versus 2.5 ± 0.8, p = 0.01) day 10 as 
shown in Fig. 5. VAP was diagnosed in 16 (55.2 %) patient 
in the selenite group compared with 21 (84 %) patients in 
the control group, (p = 0.023). Early VAP was diagnosed 
in 15(51.7 %) patients in the selenium group, whereas it 
was diagnosed in 15 (60 %) patients in the control group 
(p = 0.54). On the other hand, late VAP was diagnosed in 
5 (17.2 %) patients in the selenium group and 11 (44 %) in 
the control group (p = 0.032) as described in Table 3.
Effect of VAP on clinical outcomes We also investi-
gated the effect of VAP on the measures of health care 
resource consumptions such as duration of mechanical 
ventilation, duration of ICU and hospital stay and days 
on vasopressor support. Our results showed that there 
was no significant difference between those with early 
VAP versus no early VAP in terms of these measures. 
However, the presence of late VAP significantly increased 
the duration of mechanical ventilation (13.3  ±  1.4 ver-
sus 8.2 ± 4.8, p < 0.0001), duration of ICU stay (33 ± 17 
versus 16.5 ±  13, p  <  0.0001), duration of hospital stay 
(37 ± 22 versus 19.3 ± 15.6, p = 0.002) and days on vaso-
pressor therapy (8.3  ±  5.3 versus 2.4  ±  3, p  <  0.0001). 
Similarly, early VAP had no significant effect on the inci-
dence of reinfection (p  =  0.60), ARDS (p  =  0.47) and 
overall mortality (p = 0.54). On the other hand, there was 
significant difference between patients presented with 
late VAP versus no late VAP with respect to the incidence 
of new infection (OR 46; 95 % CI 8–259, p < 0.0001) and 
overall mortality (OR 10; 95  % CI 0.18–47, p  =  0.001), 
without statistically significant effect on the incidence of 
ARDS (p = 0.087) as depicted in Table 4.
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Discussion
In this study, 54 patients were randomized to standard 
therapy plus selenium (29 patients) and standard ther-
apy alone (25 patients) and included in the final analy-
sis despite discontinuation of selenium in patients due 
to rise in serum creatinine after 2  days of infusion. The 
baseline characteristics of the patients included were 
not significantly differing between the two groups at 
randomization as described in Table 1. The most impor-
tant striking feature in the current study was the inclu-
sion of young patients compared with previously done 
similar studies [30–33]. Our hospital is a trauma center 
level I usually giving services for trauma patients. Most 
of these patients were admitted to the ICU after car/
motorcycle injury and traumatic brain injury (TBI) was 
the most common one. This group of patients stays in 
the hospital for longer time and die because of recur-
rent hospital-acquired infections such as pneumonia 
and sepsis despite adequate resuscitation and appropri-
ate antibiotic therapy. According to new studies [34–36], 
early goal-directed therapy versus standard therapy has 
not changed mortality significantly. That tells us other 
than fluid and antibiotics, other treatment alternatives 
may have survival benefits such as high-dose selenium 
administration.
In this study, we performed a RCT to evaluate the 
effect of high dose of selenium (2 mg IV bolus during 1 h 
followed by 1.5  mg continuous infusion for 14  days) on 
Assessed for eligibility (n=364) 
Excluded (n= 310) 
♦ Not meeting inclusion criteria (n=257  ) 
• Sepsis ruled out  (n = 160 ) 
• Age < 17 yrs. (n = 52) 
• Discharged before 48 hours of ICU 
admission(n= 45) 
♦ Declined to participate (n= 2 ) 
♦ Other reasons (n=  51) 
• Therapy limitation (n=21) 
• Prior participation in similar trial (17) 
• Chronic kidney disease (n=7) 
• Brain tumor (n=6) 
Analysed (n= 29) by applying the intension-to 
treat principle
Lost to follow-up (n=0) 
Discontinued intervention due to increase in serum 
creatinine after 2 days of selenium infusion) (n= 3)  
Allocated to selenium plus standard therapy (n= 29) 
♦ Received allocated intervention (n=29)
♦ Did not receive allocated intervention  (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to standard therapy alone (n=25) 
♦ Received allocated intervention (n=25  )
♦ Did not receive allocated intervention  (n=0)




Randomized (n= 54) 
Enrollment 
Fig. 1 The profile of study design and patient selection processes
Page 6 of 12Chelkeba et al. Ann. Intensive Care  (2015) 5:29 
some clinical outcomes. The results of larger, multiple-
center trial confirmed the efficacy of high-dose sodium 
selenite supplementation in patients with severe sepsis 
and septic shock in terms of 28-day mortality reduction 
[30], along with other works [37–41]. This could not be 
confirmed in our study, as the 28-day mortality was simi-
lar in both groups. This could be due to the underpow-
ered nature of the current study. However, our result 
supported other previously done trials [22, 32] and meta-
analysis in which selenium supplementation in critically 
ill patients was not reduced 28-day mortality [24]. The 
result of our study also showed that administration of 
selenium resulted in a slight tendency toward decreas-
ing the duration of mechanical ventilation and length of 
ICU stay with little effect on the length of hospital say. 
Those who were resuscitated with selenium initially 
ended up with fewer recurrent pneumonia and sepsis 
and were weaned quicker due to cardioprotective prop-
erties of selenium against reperfusion and reoxygenation 
which may have led to sepsis-related cardiomyopathy and 
weaning failure and finally they died as result of sepsis-
related complications.
There are growing interests in carrying out researches 
in critically ill patients that incorporated biomarkers to 
optimize the treatment effects. The signaling pathways in 
inflammation and oxidative stress in vivo are quite com-
plex that in sepsis, there is always a cross talk between 
inflammation, oxidative stress and coagulation [39]. 
Measuring the effect of therapy on biomarkers of oxi-
dative stress does not necessarily reflect their effect on 
inflammatory biomarkers. Currently, we have a number 
of published articles on the effect of selenium on oxida-
tive stress in septic patients, but we rarely find articles on 
the effect of this drug on inflammatory cytokines in this 
group of patients. We investigated the effect of high-dose 
selenium on GPX activity and inflammatory cytokines 
such as IL-6, IL-8 and IL-10. Accordingly, selenium 
administration was associated with significant increase in 
the plasma activity GPX from day 3 onwards up to day 
14 as reported by many previous studies [10, 22, 30, 31] 
without no effect on the average plasma levels of the after 
mentioned three cytokines level at any point in time. 
Although we aimed to evaluate the effect of selenium on 
the inflammatory response, the study did not provide any 
new convincing insights into the mechanisms which have 
already been investigated in different clinical settings 
[42]. A more productive line of reasoning is as follows: 
lack of efficacy on cytokines could be due to the small 
Table 1 Demographic and  baseline characteristics 
of study groups
APACHE II acute physiological and chronic health evaluation II, SOFA sequential 
organ failure assessment, SSTI skin and soft tissue, CNS central nervous system, 
CR catheter line related
a Data given as media (IQR)
b Data given as mean ± SD
Characteristics Selenium (n = 29) Control (n = 25) P value
Age 35 (17–82) 41 (19–82) 0.18a
Male/femaleb 24/5 22/3 0.59
APACHE IIb 17 ± 4.3 16.4 ± 4.0 0.71
SOFAb 8 ± 2.7 8.3 ± 3 0.69
PaO2/FiO2
b 160 ± 89 150 ± 75 0.65
Sepsis, n (%) 7 (24.1) 6 (24) 0.90
Severe sepsis, n (%) 8 (27.6) 7 (28) 0.89
Septic shock, n (%) 14 (48.3) 12 (48) 0.86
Pneumonia, n (%) 18 (63) 19 (76) 0.7
Peritonitis, n (%) 7 (24) 3 (12) 0.20
SSTI infection, n (%) 3 (10) 2 (8) 0.67
CNS infection, n (%) 0 (0) 1 (4) 0.33
CR infection, n (%) 1 (3) 0 (0) 0.32
Gram positive, n (%) 4 (13.7) 1 (4) 0.20
Gram negative, n (%) 8 (27.6) 9 (36) 0.9
No growth, n (%) 17 (58.7) 15 (60) 0.87
Table 2 Changes in  the levels of  GPX, IL-6, IL-8 and  IL-10 
over time period in study patients
Data presented in mean ± SD
GPX glutathione peroxidase, IL-6 interleukin-6, IL-8 interleukin-8, IL-10 
interleukin-10
Biomarker (pg/mL) Selenium group Control group P value
Glutathione peroxidase (U/mL)
 GPX on day 0 0.185 ± 0.3 0.19 ± 0.3 0.90
 GPX on day 3 0.52 ± 0.5 0.17 ± 0.2 0.02
 GPX on day 7 0.55 ± 0.5 0.24 ± 0.3 0.032
 GPX on day 10 0.62 ± 0.2 0.33 ± 0.1 0.048
 GPX on day 14 1.1 ± 1 0.89 ± 1 0.70
IL-6 (pg/mL)
 Day 0 43.3 ± 34 37.8 ± 35.6 0.61
 Day 3 25 ± 28 32.7 ± 33.3 0.42
 Day 7 21.6 ± 27.6 18.6 ± 24 0.75
 Day 10 32.5 ± 31.8 29.8 ± 33.5 0.82
 Day 14 30.9 ± 33.8 31.4 ± 30 0.97
IL-8 (pg/mL)
 Day 0 4.1 ± 5 4 ± 5.0 0.95
 Day 3 5.7 ± 7.5 4.5 ± 6.8 0.58
 Day 7 5.8 ± 8 5 ± 6.8.0 0.78
 Day 10 4.8 ± 8 5.8 ± 5 0.73
 Day 14 6.1 ± 8 6.1 ± 9 0.99
IL-10 (pg/mL)
 Day 0 4.6 ± 3 3.6 ± 2 0.26
 Day 3 4.6 ± 3.7 4.2 ± 4.5 0.76
 Day 7 3.8 ± 2.8 5.8 ± 5.7 0.21
 Day 10 3.8 ± 3.5 6.2 ± 6 0.23
 Day 14 3.9 ± 4.6 6 ± 4.6 0.26
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sample size of the study. Second, it seems that monova-
lent approaches in isolation are unlikely to attain status 
of complete therapy due to complex interplay between 
different inflammatory pathways. Saying in another way, 
it seems that the production and release of sepsis media-
tors should be considered as a network rather than as a 
cascade; consequently, once the process is started, even 
if one of the substances responsible for the initial phase 
is blocked, other mediators will likely maintain the septic 
response [43, 44]. Therefore, as sepsis is such a complex 
disease process, it is unlike that any single agent can be 
effective for all patients. A combination strategies—the 
so-called ‘’cocktail’’—can more likely produce definitive 
results. This can be supported by previous study involv-
ing 165 patients requiring mechanical ventilation for sep-
sis or septic shock. According to this study, patients were 
randomized to receive enteral nutrition with a standard 
formula or a study formula that contained higher levels 
of omega-3 fatty acids and γ-linolenic oil, less omega-6 
fatty acids, and higher doses of the antioxidant vitamins E 
and C and selenium. Patients receiving the study formula 
had an improvement in their mortality rate, oxygenation, 
ventilator-free days, ICU-free days, and less development 
of new organ dysfunction [45].
Moreover, the short-half lives and blood levels of 
cytokines are variable, transit and non-specific so that 
their measurement might not be viable and effective way 
of monitoring the efficacy of therapeutic agent. Study 
by Landenberg G et  al. on myocardial dysfunction in 
105 severe sepsis and septic shock patients by repeated 
echocardiograms and concurrent serum inflammatory 
cytokines (IL-1β, IL-6, IL-8, IL-10, IL-18, tumor necro-
sis factor-α, and monocyte chemoattractant protein-1) 
and cardiac biomarkers [high-sensitivity troponin-T 
and N-terminal pro-B-type natriuretic peptide (NT-
proBNP)] measuring showed that none of the measured 
inflammatory cytokines correlates with systolic or dias-
tolic myocardial dysfunction in this group of patients. 
The implication of this study is that there may be no 
correlation between inflammatory cytokines in real-
life clinical setting with clinical severity of the diseases. 
Therefore, the missing effect of selenium on cytokines 
under consideration does not mean that selenium has no 
role in septic patients [46]. There is also a hypothesis that 
Fig. 2 A box plot showing changes in IL-6 over time period of study patients. Figure shows mean ± SD
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differentiation of CD4 helper cells into TH1 and TH2 is 
dependent on the delicate amount of selenium available. 
However, Selenium supplementation boosts T cell recep-
tor signals and skews differentiation toward a Th1 pheno-
type and Selenium deficiency leads to low T cell receptors 
signals and skews differentiation toward lowered activa-
tion states with a bias toward a Th2 phenotype; adequate 
selenium intake does not bias T cell differentiation so 
that the cytokines released are balanced, which could be 
the reason why we could not see the effect of selenium in 
this study [42].
The mean SOFA respiratory scores, which assess the 
degree of respiratory dysfunction decreased significantly 
in selenium group, compared with the control on days 7 
and 10. This indicates that selenium supplementation in 
critically ill patients reduces pulmonary infections and 
thereby improves pulmonary function. A study showed 
that in patients with severe burn trauma, an adjuvant 
selenium substitution reduced mainly pulmonary infec-
tions [47]. Moreover, the administration of high-dose 
selenium was associated with significant reduction of 
occurrence of VAP. Although the occurrence of late VAP 
was significantly reduced, there was no significant differ-
ence with regard to occurrence of early VAP between the 
two groups; a result opposite with that of Manzanares 
et  al. [33],where selenium supplementation in critically 
ill patients with SIRS associated with significant reduc-
tion in early VAP. The explanation for the discrepancy is 
that peripheral tissues represent a large and slowly recy-
cling pool. The tissue selenium concentration increases 
at a lower rate to the normal level compared with the 
plasma concentration and it begins to increase after sele-
nium supplementation for 2 days and then continues to 
increase slowly for several weeks [43].Therefore, it makes 
sense that selenium supplementation slowly increases 
the intracellular concentration of selenium and the activ-
ity of glutathione peroxidase-3, an enzyme that prevents 
the damaging of endothelial cells and the adherence of 
bacteria into the respiratory mucosal cells and thereby 
infection. From this perspective, it is logical if selenium 
supplementation prevents late-onset VAP which happens 
in patients after 5 or more days on mechanical ventila-
tion. Nevertheless, it is conceivable from the two stud-
ies that the contribution of VAP to mortality and ICU 
Fig. 3 A box plot showing changes in IL-8 over time period of study patients. Figure shows mean ± SD
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Fig. 5 Changes in the mean SOFA respiratory scores in study patients over time period. Figure shows mean ± SD
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resource consumption makes prevention an attractive 
approach, one of which selenium is proposed as novel 
strategy for inclusion into the bundles for VAP preven-
tion [29]. The damaging of pulmonary interstitial and 
alveolar spaces in the lung begins with the interaction of 
immune cells with the endothelial cells, which stimulates 
the later to express surface adhesion molecules that bind 
to the neutrophils and facilitate their migration into the 
interstitial and alveolar spaces. There is also concomi-
tant triggering of free radical bursts into the lungs [33]. 
Selenium being antioxidant and anti-inflammatory plays 
a great role here by increasing the activity of glutathione 
peroxidase. Unfortunately, suboptimal immune func-
tion in patients with selenium deficiency was observed, 
whereby the functions of both innate and acquired 
immune system impaired and leading to infection, multi-
ple organs failure and hospital-acquired pneumonia [21]. 
Our study similarly showed that selenium supplementa-
tion reduced VAP and reinfection as well. There are also 
a couple of supporting ideas from Scottish Intensive Care 
Glutamine or Selenium Evaluative Trial (SIGNET) [23] 
and Berger et al. [47, 48] that enhancing trace elements in 
critically ill patients is associated with decreased hospi-
tal-acquired infections such as episodes of VAP.
Our analyses included versatile directions in that we 
also did analysis of the effect of VAP on overall mortal-
ity, the incidences of reinfection and ARDS and health 
care resource consumption measures such as duration 
of mechanical ventilation, duration of ICU and hospital 
stay, days on vasopressor therapy to explore the indirect 
beneficial effects of selenium on these clinical outcomes. 
Accordingly, we found that patients presented with late 
VAP had significantly longer duration of mechanical ven-
tilation, ICU stay, hospital stay and vasopressor therapy 
compared to those without late VAP. The presence of late 
VAP was also associated with higher overall mortality, 
higher incidence of new infection and ARDS, a result in 
line with some previously done studies [13, 49–52]. On 
Table 3 Clinical outcomes of study patients
SOFA sequential organ failure assessment, EVAP early ventilator-associated pneumonia, LVAP late ventilator-associated pneumonia, ICU intensive care unit
Outcome (s) Selenium group (n = 29) Control group (n = 25) P value
SOFA respiratory score
 Day 0 2.3 ± 0.8 2.4 ± 0.8 0.82
 Day 3 2.5 ± 0.9 2.4 ± 0.9 0.69
 Day 7 2.1 ± 1 2.7 ± 1 0.03
 Day 10 1.6 ± 1.2 2.5 ± 0.8 0.01
 Day 14 2.2 ± 1.4 2.4 ± 0.9 0.77
 VAP, n (%) 16 (55.2) 21 (84) 0.023
 Early VAP, n (%) 15 (51.7) 15 (60) 0.54
 Late VAP, n (%) 5 (17.2) 11 (44) 0.032
 Duration of mechanical ventilation (in days), mean ± SD 8.9 ± 5 10.7 ± 4.5 0.17
 Length of ICU stay (in days), mean ± SD 19.7 ± 11 23.8 ± 13 0.37
 Lengths of hospital stay (in days), mean ± SD 25.2 ± 10 24.5 ± 9 0.87
 28-day mortality, n (%) 9 (31) 10 (40) 0.49
Table 4 The effect of VAP on clinical outcomes in study patients
DOMV duration of mechanical ventilation, ICU intensive care unit, VAP ventilator-associated pneumonia, ARDS acute respiratory distress syndrome, SD standard 
deviation, OR odds ratio
Outcome (s) Early VAP OR [95 % CI] P Late VAP OR [95 % CI] P value
Yes No Yes No
DOMV, mean ± SD 10.6 ± 4 8.6 ± 5.5 0.17 13.3 ± 1.4 8.2 ± 4.8 <0.0001
Duration of ICU stay, mean ± SD 22.9 ± 15.5 20 ± 17.9 0.54 33 ± 17 16.5 ± 13.4 <0.0001
Duration of hospital stay, mean ± SD 25.5 ± 17 24 ± 23 0.78 37 ± 22 19.3 ± 15.6 0.002
Days on vasopressor therapy, mean ± SD 3.4 ± 4 5.5 ± 5 0.13 8.3 ± 5.3 2.4 ± 3 <0.0001
Incidence of new infection, n/N 8/33 8/21 0.6 [0.18–2] 0.60 13/19 3/35 46 [8–259] <0.0001
Incidence of ARDS, n/N 3/33 4/21 0.57 [0.11–2.8] 0.47 4/19 3/35 3.9 [0.76–20] 0.087
Overall mortality, n/N 16/33 13/21 0.97 [0.33–2.8] 0.54 14/19 15/35 10 [1.8–47] 0.001
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the other hand, there was no significant difference in 
terms of the mortality, incidence of reinfection or ADRS 
and resource consumption measures in patients with 
early VAP compared to those with no early VAP.
Our study has a couple of strengths. First, we admin-
istered selenium within the time frame of early goal-
directed therapy to evaluate its effect early in sepsis, a 
strategy found to reduce the mortality rate significantly 
in patients with severe sepsis and septic shock [53, 54], 
although this issue becomes a controversial issue at this 
moment [34–36]. Second, we investigated the effects of 
VAP on different outcomes on mechanically ventilated 
septic patients for 5 or more days, which is very impor-
tant for clinicians caring for such patients to take action 
ahead of the occurrence and the hospital as a whole to 
reduce the resource consumption. However, our study 
was not without limitations. Interpretation of the result 
of our study should be in caution since our sample size 
was underpowered to detect the expected differences 
between the two groups in terms of outcomes. It is also 
important to mind that our study was single centered 
which did not include patients from different geographi-
cal areas, ethnicity and limited number of females and 
therefore it perhaps lacked external validity. Furthermore, 
the study period was relatively long to enroll the required 
number of participants. Unfortunately, the number of 
participants enrolled was much below our plan since we 
are caring for much debilitated patients referred from 
other centers around that require intensive monitoring 
and our restricted inclusion criteria. Finally, it is perceiv-
able that the current study was single blind study which 
could possibly introduce bias to the outcomes.
Conclusion
High-dose selenium administration within the time 
frame of early goal-directed therapy was not resulted in 
reduction of 28-day mortality, but increased the activity 
of glutathione peroxidase with no effect on the levels of 
inflammatory cytokines at any point in time in mechani-
cally ventilated septic patients. However, selenium 
supplementation in mechanically ventilated patients 
following sepsis was associated with reduced occur-
rence of VAP. We also observed that late-onset VAP has 
a significant effect on clinical outcomes and health care 
resource consumption measures. It is prudent to evaluate 
the result of this study by an adequately powered, rand-
omized, placebo-controlled trial of high methodological 
value.
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